Rosario Liberti

Dr. Rosario Liberti

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2024 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
Antonella Di PaoloAntonella Di Paolo
Antonella Di Paolo
RLRosario Liberti
Rosario Liberti
LALucia Anzalone
Lucia Anzalone
CCClaudia Colabella
Claudia Colabella
AFAndrea Felici
Andrea Felici
MCmonica cagiola
monica cagiola
Background: Veterinary autogenous vaccines, similar to all injectable pharmaceutical products, must be tested to assess endotoxin concentrations. The Limulus Amebocyte Lysate Test (LAL test) is widely used in in vitro quality control assays for endotoxin detection, although it presents some ethical issues related to the production of reagents and is also characterized by a low specificity due to other contaminants that can activate the reaction. For all these reasons, a new recombinant factor C LAL test was developed. Aim: In this study, we described the comparison between two LAL test methods for in vitro quality control of veterinary autogenous vaccines, with the aim of evaluating the most suitable method and establishing an endotoxin concentration range for two different matrices. Methods: Two hundred batches of two different vaccine matrices were tested using the kinetic chromogenic LAL test and recombinant factor C endotoxin detection assay commercial kits. Results and Conclusions: Statistical analysis conducted after the validation of the recombinant factor C test exhibited a statistically significant correlation between the two methods and for both vaccine matrices, suggesting that the animal-free assay can be used as a routine quality control test for veterinary autogenous vaccines.

6 August 2026 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
Antonella Di PaoloAntonella Di Paolo
Antonella Di Paolo
RLRosario Liberti
Rosario Liberti
LALucia Anzalone
Lucia Anzalone
CCClaudia Colabella
Claudia Colabella
AFAndrea Felici
Andrea Felici
MCmonica cagiola
monica cagiola
Background: Veterinary autogenous vaccines (AVs) are emergency tools produced in a short timeframe from bacterial/viral/fungal isolates when commercial vaccines are not available and undergo strict quality assurance and safety tests before release. In accordance with the European Directive 2010/63/EU and the 3R principles, we evaluated for the first time the possible substitution of the final toxicity in vivo test (abnormal toxicity test) with an alternative cell-based and embryo-based assay. Methods: The five most requested different autogenous matrices (adopted to produce a customizable number of lots requested from customers) were tested in vitro in parallel for residual toxicity by in vitro fish embryo acute toxicity (FET) test and cytotoxicity assay (MTS) using serial dilutions, together with the authorized in vivo test. Results: Statistical analysis revealed different outcomes between the two in vitro methods, highlighting the greater discriminatory power of the MTS assay compared to the other, with results more like the observed in vivo ATT outcome (pass/negative). Conclusions: In this preliminary first dataset, FET appeared poorly compatible with several complex autogenous vaccine matrices, while the L929 MTS assay yielded interpretable viability thresholds for all tested matrices. These findings support further qualification of MTS as part of an integrated non-animal batch characterization strategy, but they do not yet establish replacement of the in vivo test for veterinary autogenous vaccine quality control.